Application of Medipterocarpin in preparation of medicine for preventing and / or treating immunosuppressive diseases

Abstract

The invention belongs to the field of biological medicines, and particularly relates to application of medicarpin in preparation of medicines for preventing and / or treating immunosuppressive diseases. According to the application disclosed by the invention, it is found that the mendalin can increase the content of IL-3 and M-CSF in serum, reduce the content of EPO and increase the content of IL-34 and IL-15 in bone marrow at the same time; and the red sandalwood can increase the number of leukocytes, platelets and basophilic granulocytes in peripheral blood and enhance the multiplication capacity of bone marrow cells, so that the red sandalwood can be used for preventing and / or treating the immunosuppressive diseases, and is further used for preparing the medicines for preventing and / or treating the immunosuppressive diseases.

Description

Technical Field

[0001] This invention belongs to the field of biomedicine, and in particular relates to the use of thymol in the preparation of drugs for the prevention and / or treatment of immunosuppressive diseases. Background Technology

[0002] The immune system is a vital system in the body that executes immune responses and functions. It consists of immune organs, immune cells, and immune molecules. The immune system recognizes and eliminates antigenic foreign substances and coordinates with other systems in the body to maintain homeostasis and physiological balance. Decreased immunity can lead to various defects in the immune system, resulting in changes in the number of monocytes and macrophages, affecting their phagocytic capacity and chemotactic responses, making the body more susceptible to pathogens and causing a range of clinical symptoms.

[0003] Many traditional Chinese medicines, their extracts, and compounds can regulate the body's immune function. For example, the aqueous extract of Achyranthes bidentata has an improving effect on the immune function of mice with cyclophosphamide-induced immunosuppression. The polysaccharide from Kuding tea and Ilex chinensis can enhance the immune activity of splenic lymphocytes in mice by promoting lymphocyte proliferation, enhancing cellular antioxidant capacity, and inducing the secretion of inflammatory cytokines, thus exerting its immunomodulatory effect. Other polysaccharides such as Atractylodes macrocephala, Platycodon grandiflorus extract, Cordyceps sinensis, Antrodia camphorata, and cinnamon can also improve the immune function of mice.

[0004] Medistigmine is a flavonoid compound with a pterostilbene nucleus structure, primarily derived from medicinal herbs such as *Spatholobus suberectus*, *Astragalus membranaceus*, and *Panax ginseng*. *Spatholobus suberectus* is a blood-activating and stasis-removing herb with blood-nourishing effects; *Astragalus membranaceus* is a qi-tonifying herb with qi-tonifying, yang-raising, fluid-generating, and blood-nourishing effects; and *Panax ginseng* has blood-activating and pain-relieving effects. However, there are no reports on the application of medissangine in the prevention and / or treatment of immunosuppressive diseases.

[0005] Summary of the Invention

[0006] Through in-depth research and pharmacological experiments, the inventors of this application discovered that medroxypyridine significantly promotes the number of leukocytes, platelets, and basophils in the peripheral blood of mice with cyclophosphamide-induced immunosuppressive diseases, enhances the vitality and hematopoietic capacity of bone marrow cells, and regulates the levels of cytokines IL-3, M-CSF, EPO, IL-15, and IL-34, thereby restoring the immune function of mice with immunosuppressive diseases.

[0007] The first aspect of this application provides the use of thymol in the preparation of a medicament for the prevention and / or treatment of immunosuppressive diseases in a subject.

[0008] In some embodiments of this application, medroxylin increases the number of leukocytes, platelets and basophils in peripheral blood, enhances the activity and hematopoietic capacity of bone marrow cells, increases the levels of IL-3 and M-CSF in serum, decreases the level of EPO, and simultaneously increases the levels of IL-15 and IL-34 in bone marrow in subjects with immunosuppressive diseases.

[0009] Therefore, the present invention also relates to the use of thymol in the preparation of a medicament for improving the reduction in the number of white blood cells, platelets, and basophils caused by immunosuppression in subjects. Further, the immunosuppression may be chemotherapy-induced immunosuppression.

[0010] In some embodiments of this application, the immunosuppressive disease includes hematologic disorders.

[0011] In some embodiments of this application, the immunosuppressive disease includes chemotherapy-induced immunosuppressive diseases, such as chemotherapy-induced hematologic disorders.

[0012] In some embodiments of this application, the hematologic disorders include at least one of leukopenia, thrombocytopenia, systemic lupus erythematosus, rheumatoid arthritis, aplastic anemia, and autoimmune hemolytic anemia.

[0013] A second aspect of this application provides a pharmaceutical composition for the prevention and / or treatment of immunosuppressive diseases, comprising medroxylin.

[0014] In some embodiments of this application, the santalin is provided in monomeric form or in the form of a plant extract comprising it.

[0015] In some embodiments of this application, the plant extract is selected from chicken blood vine, astragalus, or ginseng extract.

[0016] In some embodiments of this application, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier or excipient.

[0017] In some embodiments of this application, the pharmaceutically acceptable carrier or excipient is selected from at least one of solvents, diluents, disintegrants, precipitation inhibitors, surfactants, flow aids, binders, lubricants, dispersants, suspending agents, isotonic agents, thickeners, emulsifiers, preservatives, stabilizers, hydrating agents, emulsification accelerators, buffers, absorbents, colorants, flavorings, sweeteners, ion exchangers, release agents, coating agents, flavoring agents, or antioxidants.

[0018] In some embodiments of this application, the pharmaceutical composition is formulated as any one of the following dosage forms: powder, tablet, capsule, pill, drop pill, emulsion, suspension, or tincture.

[0019] Beneficial effects of the present invention

[0020] Medicin can increase the levels of IL-3 and M-CSF in serum, decrease the level of EPO, and increase the levels of IL-34 and IL-15 in bone marrow. Furthermore, Medicin can increase the number of leukocytes, platelets, and basophils in peripheral blood, enhance the activity of bone marrow mononuclear cells, and increase the proportion of HSPCs. Therefore, it can be used to prevent and / or treat immunosuppressive diseases, and thus be used to prepare drugs for the prevention and / or treatment of immunosuppressive diseases. Attached Figure Description

[0021] Figure 1A A bar chart showing the number of white blood cells in peripheral blood.

[0022] Figure 1B A bar chart of platelet counts in peripheral blood;

[0023] Figure 1C Bar chart showing the number of basophils and monocytes in peripheral blood.

[0024] Figure 2A A bar chart showing the number of mononuclear cell colonies formed in the bone marrow;

[0025] Figure 2B Bar chart of thymus index and spleen index;

[0026] Figure 2C : Bar chart of serum cytokine levels;

[0027] Figure 2D Bar chart of cytokine levels in bone marrow;

[0028] Figure 2E : Bar chart of the proportion of HSPCs in bone marrow; (n=5, compared with the Con group, # p<0.05, ## p<0.01, ### p<0.001; compared with the Mod group, *p<0.05, **p<0.01, ***p<0.001). Detailed Implementation

[0029] The first aspect of this application provides the use of styrax medroxylin in the preparation of medicaments for the prevention and / or treatment of immunosuppressive diseases.

[0030] Through in-depth research, the inventors of this application discovered that medroxylin can increase the levels of IL-3 and M-CSF in serum, decrease the level of EPO, and simultaneously increase the levels of IL-34 and IL-15 in bone marrow. Furthermore, medroxylin can increase the number of leukocytes, platelets, and basophils in peripheral blood and enhance the proliferation of bone marrow cells, thereby making it useful for the prevention and / or treatment of immunosuppressive diseases, and further for the preparation of drugs for the prevention and / or treatment of immunosuppressive diseases.

[0031] In this application, the term "treatment" has its general meaning, and specifically refers to the treatment of a mammalian individual (preferably a human) already suffering from an immunosuppressive disease with the drug of this application, with the aim of producing a therapeutic, curative, alleviating, or reducing effect on the disease. Similarly, the term "prevention" as used in this application has its general meaning, and specifically refers to the treatment of a mammalian individual who may suffer from or is at risk of suffering from an immunosuppressive disease with the drug of this application, with the aim of producing a preventative, preventive, blocking, or isolating effect on the disease.

[0032] In some embodiments of this application, the immunosuppressive disease includes hematologic disorders. In some embodiments of this application, the immunosuppressive disease includes chemotherapy-induced immunosuppressive diseases, such as chemotherapy-induced hematologic disorders.

[0033] In some embodiments of this application, the hematologic disorders include at least one of leukopenia, thrombocytopenia, systemic lupus erythematosus, rheumatoid arthritis, aplastic anemia, and autoimmune hemolytic anemia.

[0034] In this application, the term "subject" refers to a mammal, such as a primate mammal, such as a human.

[0035] The santalin in this application is mainly used for people with weakened immune systems, such as the elderly, children, or seriously ill patients; it can be used to prevent and / or treat immunosuppressive diseases, including but not limited to the types of diseases mentioned above.

[0036] A second aspect of this application provides a pharmaceutical composition for the prevention and / or treatment of immunosuppressive diseases, comprising medroxylin.

[0037] In some embodiments of this application, the santalin is provided in monomeric form or in the form of a plant extract comprising it.

[0038] In some embodiments of this application, the plant extract is selected from chicken blood vine, astragalus, or ginseng extract.

[0039] This application does not impose any particular restrictions on the extraction method of chicken blood vine, astragalus or blood ginseng extract. Those skilled in the art can extract it using existing techniques. For example, chicken blood vine, astragalus or blood ginseng can be refluxed with 60-80 vol% methanol aqueous solution or ethanol aqueous solution at a material-to-liquid mass-to-volume ratio of 1g:6-10mL for 3-5 hours at room temperature for 2-3 times to obtain an extract containing mediocreosote.

[0040] In some embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier or excipient.

[0041] In this application, "pharmaceutical acceptable" means that when used at the usual dosage, it has no substantial toxic effects and is therefore approved by a government or equivalent international organization or has been approved for use in animals, more particularly in humans, or is listed in a pharmacopoeia.

[0042] The "pharmaceutically acceptable carrier or excipient" used in the pharmaceutical composition of this application can be any conventional carrier in the field of pharmaceutical formulation, and the choice of a specific carrier will depend on the route of administration or the type and state of disease for treating a specific patient. The preparation method of a suitable pharmaceutical composition for a specific route of administration is entirely within the knowledge of a person skilled in the pharmaceutical art. For example, pharmaceutically acceptable carriers or excipients include solvents, diluents, disintegrants, precipitation inhibitors, surfactants, flow aids, binders, lubricants, dispersants, suspending agents, isotonic agents, thickeners, emulsifiers, stabilizers, hydrating agents, emulsification accelerators, buffers, absorbents, colorants, ion exchangers, release agents, coating agents, flavoring agents, and antioxidants, etc., which are conventional in the pharmaceutical field. If necessary, flavoring agents, preservatives, and sweeteners may also be added to the pharmaceutical composition.

[0043] The term "pharmaceutical composition" as used in this application has its general meaning. Furthermore, the "pharmaceutical composition" of this application may also exist or be provided in the form of health products, functional foods, foods, food additives, etc. The active ingredients of the raw materials for the pharmaceutical composition of this application can be obtained using conventional techniques in the pharmaceutical field, particularly in the formulation field, through extraction, separation, and purification methods commonly used in pharmaceutical production. These ingredients are optionally mixed with one or more pharmaceutically acceptable carriers or excipients to form the desired dosage form, thereby preparing the pharmaceutical composition of this application. According to this application, the pharmaceutical composition can be a pharmaceutical preparation suitable for oral administration, a pharmaceutical preparation suitable for parenteral injection (e.g., intravenous injection, subcutaneous injection) (e.g., a solution), a pharmaceutical preparation suitable for topical administration (e.g., an ointment, patch, or cream), or a pharmaceutical preparation suitable for rectal administration (e.g., a suppository), etc. Dosage forms for oral administration may include, but are not limited to, tablets, pills, drops, hard or soft capsules, solutions, suspensions, emulsions, tinctures, syrups, powders, granules, pellets, small pills, elixirs, etc. In addition to the active ingredient, these formulations may also contain diluents (e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, and glycine), lubricants (e.g., silica, talc, stearic acid or its magnesium or calcium salts, and polyethylene glycol). Tablets may also contain binders such as magnesium aluminum silicate, starch paste, gelatin, astragalus gum, methylcellulose, sodium carboxymethyl cellulose, and polyvinylpyrrolidone. Where necessary, they may also contain pharmaceutical additives such as disintegrants (e.g., starch, agar, alginate or its sodium salts), absorbents, colorants, flavorings, sweeteners, etc. Tablets may be prepared using commonly used mixing, granulation, or coating methods.

[0044] The pharmaceutical composition of this application uses a pharmaceutically acceptable dose of medroxylin, i.e., the dosage, which can be varied based on the age, sex, and weight of the patient to be treated, the specific disease or pathological condition to be treated, the severity of the disease or pathological condition, the route of administration, and the diagnostician's judgment. The dosage is determined taking these factors into account and is within the range of those skilled in the art. A typical dosage may be 1-300 mg / kg / day, specifically 10-60 mg / kg / day. However, the scope of this application is not limited in any way to the stated dosage.

[0045] The present invention will be further illustrated below with reference to specific embodiments, but the embodiments do not limit the present invention in any way. Unless otherwise specified, the reagents, methods, and equipment used in the present invention are conventional reagents, methods, and equipment in this technical field.

[0046] Example 1: Effects of Medicin on Peripheral Blood Counts in Immunosuppressive Mice I. Experimental Materials

[0047] 1.1 Experimental Reagents

[0048] Table 1: Detailed Information on Experimental Reagents and Consumables

[0049]

[0050] 1.2 Experimental Apparatus

[0051] Table 2: Detailed Information on Experimental Instruments

[0052]

[0053] 1.3 Experimental Animals and Grouping

[0054] SPF-grade male C57BL / 6 mice, 5 weeks old and weighing 20±2g, were randomly divided into 7 groups of 5 mice each. The mice were administered the following treatments by gavage: normal control group (Con, 0.9% saline), control group (Con+Med 10mg / kg / d), model group (Mod, 0.9% saline), low-dose Med group (Med-L, 1mg / kg / d), medium-dose Med group (Med-M, 5mg / kg / d), high-dose Med group (Med-H, 10mg / kg / d), and positive control Leucogen group (Leucogen, 20mg / kg / d). The administration volume was 0.15mL / 10g, administered once daily for 15 consecutive days.

[0055] II. Experimental Methods

[0056] 2.1 Establishment of a mouse model of immunosuppressive disease

[0057] On the first day of the experiment, the mice were administered the drug via gavage. From the 5th to the 7th day of administration, except for the normal group and the control group, the other groups were injected intraperitoneally once a day with 80 mg / kg cyclophosphamide (i.e., the volume of 8 mg / mL cyclophosphamide solution administered was 0.1 mL / 10 g). The mice in the normal group and the control group were injected intraperitoneally with an equal volume of physiological saline.

[0058] 2.2 Sample Collection

[0059] Tail blood was collected 24 hours after the last administration for routine blood tests.

[0060] 2.3 Complete blood count (CBC)

[0061] A five-part differential hematology analyzer was used to perform routine blood tests, and the number of white blood cells, platelets, neutrophils, monocytes, and other blood cells in the tail blood of mice was recorded.

[0062] III. Experimental Results

[0063] 3.1 Medicin can increase the number of leukocytes in the peripheral blood of mice with immunosuppressive diseases.

[0064] The number of white blood cells in peripheral blood is an effective indicator for evaluating improvement in leukopenia. Complete blood count results show ( Figure 1A After 15 days of intervention with 5 mg / kg / d of thymol, the number of white blood cells in the peripheral blood of mice with chemotherapy-induced immunosuppressive diseases was significantly increased, demonstrating a significant white blood cell-boosting effect.

[0065] 3.2 Medicin can increase the number of platelets in the peripheral blood of mice with immunosuppressive diseases.

[0066] The number of platelets in peripheral blood is an effective indicator for evaluating improvement in thrombocytopenia. For example... Figure 1B The results showed that the number of platelets in the peripheral blood of mice with immunosuppressive diseases was significantly reduced; compared with the model group, the number of platelets was significantly increased after intervention with medroxypyridine.

[0067] 3.3 Medisin can increase the number of basophils in the peripheral blood of mice with immunosuppressive diseases.

[0068] like Figure 1C The results showed that, compared with the model group, the number of basophils in the peripheral blood of mice with immunosuppressive diseases was significantly increased after intervention with medroxypyridine.

[0069] Example 2: Effects of Medicin on Hematopoietic Function in Immunosuppressive Mice I. Experimental Materials

[0070] 1.1 Experimental Reagents

[0071] Table 3: Detailed Information on Experimental Reagents and Consumables

[0072]

[0073]

[0074] 1.2 Experimental Apparatus

[0075] Table 4: Detailed Information on Experimental Instruments

[0076]

[0077] 1.3 Experimental Animals and Grouping

[0078] SPF-grade male C57BL / 6 mice, 5 weeks old and weighing 20±2g, were selected and randomly divided into 3 groups of 5 mice each. The mice were given the specified gavage treatments: normal control group (Con), model group (Mod, 0.9% saline), and Med treatment group (Med, 5mg / kg / d). The administration volume was 0.15mL / 10g, once a day for 15 consecutive days.

[0079] II. Experimental Methods

[0080] 2.1 Dosing regimen and sample collection

[0081] Twenty-four hours after the last administration, the patient was euthanized by cervical dislocation, and serum was collected for cytokine content determination. The thymus and spleen were harvested for calculating the thymus index and spleen index. The femur was harvested for bone marrow nucleated cell counting, colony formation assay, bone marrow cytokine determination, and detection of the proportion and absolute number of bone marrow HSPCs.

[0082] 2.2 Bone marrow nucleated cell count

[0083] After euthanizing mice by cervical dislocation, the femur was immersed in 75% alcohol for 2 minutes. Under aseptic conditions, the femur was removed, and the muscles and connective tissue on the femur were removed with sterile gauze. 1 mL of DMEM culture medium was drawn using a syringe, and the bone marrow was flushed from the medullary cavity into a 1.5 mL sterile EP tube, repeated 3-5 times to ensure complete flushing. The cells were then mixed thoroughly with a pipette to prepare a single-cell suspension. 20 μL of the cell suspension was diluted to 1 mL with DMEM culture medium, and 10 μL of the diluted solution was dropped into the sample wells of an automated cell counting chamber and inserted into an automated cell counter for counting.

[0084] 2.3 Colony Formation Experiment

[0085] The cell suspension from step 2.2 was filtered through a 70 μm microporous membrane. The collected cell suspension was slowly added along the wall of a centrifuge tube to the top of an equal volume of Ficoll lymphocyte separation medium, and centrifuged at 2000 rpm for 20 min. After centrifugation, the liquid separated into layers; the milky white, cloudy layer in the middle was the bone marrow mononuclear cells. The bone marrow mononuclear cells were aspirated, washed twice with 5 times their volume of culture medium, resuspended, and counted using an automated cell counter. The cell density was adjusted to 3 × 10⁻⁶ cells / mL. 5 / mL. Add 500μL of cell suspension to 5mL of M3434 methylcellulose medium and vortex vigorously to achieve a cell density of approximately 3×10⁹ / mL. 4 / mL. Spread 1 mL of cell suspension evenly into each well of a 24-well plate and incubate at 37°C, 5% CO2, and saturated humidity. After 8–10 days of incubation, observe under a microscope and count the number of colonies. A cell cluster with more than 50 cells is considered one colony for counting and statistical analysis.

[0086] 2.4 Organ Index Measurement

[0087] Carefully remove the thymus and spleen with tweezers, keeping the organs intact. After absorbing the liquid on the surface of the organs with absorbent paper, weigh them. The ratio of their weight to body weight is the thymus index and spleen index, with the unit being mg / 10g.

[0088] 2.5 Cytokine Level Measurement

[0089] Mouse serum and bone marrow supernatant were collected and processed using LEGENDplex. TM The MU Hematopoietic Stem Cell Panel kit measures cytokine levels.

[0090] 2.6 Detection of the absolute number and proportion of HSPCs in bone marrow of model animals

[0091] Mouse bone marrow cells were collected, dispersed in PBS, passed through a membrane, washed, counted, labeled with antibodies (lineage, Sca-1, CD117, CD34, CD135, etc.), incubated at 4°C for 30 min, resuspended in PBS, and prepared into a cell suspension for flow cytometry analysis.

[0092] III. Experimental Results

[0093] 3.1 Medicin can increase the activity of bone marrow cells in mice with immunosuppressive diseases.

[0094] Colony formation assays are an effective way to evaluate the effects of drugs on cell viability. Results showed that medroxypyr significantly increased the number of colonies on bone marrow mononuclear cells in immunosuppressive mice. Figure 2A It has a significant promoting effect on the activity of bone marrow cells.

[0095] 3.2 Medicin had no significant effect on organ indices in mice with immunosuppressive diseases.

[0096] Organ index results showed that after 15 days of intervention with thymol, there was no significant effect on the thymus index and spleen index in mice with immunosuppressive diseases. Figure 2B This indicates that medroxypyr does not affect its extramedullary hematopoietic capacity.

[0097] 3.3 Medisin can reverse the levels of hematopoietic cytokines and restore bone marrow hematopoietic homeostasis.

[0098] The proliferation and differentiation of bone marrow cells involve multiple cytokines, and changes in cytokine levels reflect alterations in hematopoietic capacity. Results from cytokine analysis in mouse serum and bone marrow showed that medroxypyr significantly increased serum IL-3 and M-CSF levels and decreased EPO levels. Figure 2C ); at the same time, it increases the levels of IL-34 and IL-15 in the bone marrow ( Figure 2D ).

[0099] 3.4 Medicin can increase the bone marrow hematopoietic capacity of mice with immunosuppressive diseases.

[0100] The proportion and absolute number of HSPCs in the bone marrow reflect changes in hematopoietic function. Flow cytometry results showed that intervention with medroxypyridine increased the proportion and absolute number of HSPCs in the bone marrow, especially LSK. -, HPCs, ST-HSCs, MPP and CLP ( Figure 2E This indicates that medroxypyr has a significant effect on improving bone marrow hematopoietic function.

[0101] in conclusion

[0102] Based on modern pharmacological research methods, this invention systematically investigated the pharmacological effects of medroxypyrin in treating immunosuppressive diseases, and clarified that medroxypyrin can significantly increase the number of white blood cells in the peripheral blood of mice with cyclophosphamide-induced immunosuppressive diseases, while improving the number of platelets and basophils in the peripheral blood, and has a significant therapeutic effect on chemotherapy-induced immunosuppressive diseases.

[0103] Bone marrow is the direct source of mature blood cells. The number of bone marrow cell colonies and the proportion and absolute number of bone marrow HSPCs can effectively reflect the hematopoietic function of bone marrow. The spleen, as an extramedullary hematopoietic organ, also plays a crucial role in hematopoiesis. This invention found that santalin significantly improved the activity of bone marrow cells and the proportion of bone marrow HSPCs in mice with immunosuppressive diseases, but did not affect the spleen index, indicating that santalin mainly exerts its effect by regulating bone marrow hematopoiesis. This invention further used flow cytometry to clarify that santalin intervention significantly reversed the decrease in the proportion of ST-HSCs and MPP in mouse bone marrow and increased LSK. - The number of HPCs and CLPs. Among them, LSK... - HPCs, ST-HSCs, and MPPs are hematopoietic stem / progenitor cells with strong differentiation capabilities, indicating that Medicin can effectively improve the hematopoietic function of bone marrow hematopoietic stem / progenitor cells. On the other hand, CLPs are lymphoid progenitor cells that can further differentiate into immune cells such as T cells, B cells, and NK cells, playing a crucial role in the body's immune and inflammatory responses. In conclusion, Medicin has a significant ameliorative effect on immunosuppressive diseases.

[0104] Cytokines are one of the main pathways for intercellular signal transduction. Immunocytokines participate in the regulation of various immune cell biological functions and are key mechanisms for immune function regulation. Among them, IL-3, produced by T lymphocytes, can stimulate the proliferation and differentiation of cells involved in the immune response and enhance their function. M-CSF is a hematopoietic growth factor that regulates the survival, proliferation, differentiation, and function of mononuclear phagocytes. EPO has anti-inflammatory and stress-protective effects. IL-15 can enhance the proliferative activity of NK cells, promote the activation of lymphocytes and myeloid cell subsets, maintain immune cell homeostasis, and promote immune system reconstruction. IL-34 can promote the proliferation of Th17 cells. This invention found that erythritol can significantly increase the levels of IL-3 and M-CSF in the serum of mice with immunosuppressive diseases, decrease the level of EPO, and simultaneously increase the levels of IL-34 and IL-15 in the bone marrow. Therefore, it is indicated that erythritol mainly participates in the regulation of immune and inflammation-related biological processes, can improve immunosuppression and inflammatory responses, and promote the recovery of immunosuppressive diseases.

[0105] It should be noted that while the preferred embodiments of the present invention are provided in this specification, the present invention can be implemented in many different forms and is not limited to the embodiments described herein. These embodiments are not intended to impose additional limitations on the content of the present invention; their purpose is to provide a more thorough and comprehensive understanding of the disclosure of the present invention. Furthermore, the above-described technical features can be combined with each other to form various embodiments not listed above, all of which are considered to be within the scope of the present invention. Moreover, those skilled in the art can make improvements or modifications based on the above description, and all such improvements and modifications should fall within the protection scope of the appended claims.

Claims

1. Use of medermycin in the preparation of a medicament for preventing and / or treating an immunosuppressive disease.

2. Use according to claim 1, characterized in that, Medermycin increases the number of white blood cells, platelets and basophils in peripheral blood, enhances the viability and hematopoietic capacity of bone marrow cells, and increases the content of IL-3 and M-CSF in serum, decreases the content of EPO and simultaneously increases the content of IL-15 and IL-34 in bone marrow in a subject having an immunosuppressive disease.

3. Use according to claim 1, characterized in that, The immunosuppressive disease includes a hematological disease.

4. Use according to claim 3, characterized in that, The hematological disease includes at least one of leukopenia, thrombocytopenia, systemic lupus erythematosus, rheumatoid arthritis, aplastic anemia, and autoimmune hemolytic anemia.

5. A pharmaceutical composition for preventing and / or treating an immunosuppressive disease, comprising medermycin.

6. The pharmaceutical composition of claim 5, wherein, The medermycin is provided in a form of a monomer or a plant extract comprising the same.

7. The pharmaceutical composition of claim 6, wherein, The plant extract is selected from the group consisting of a Caesalpinia Sappan, a Radix Astragali or a Blood Ginseng extract.

8. The pharmaceutical composition according to any one of claims 5 to 7, characterized in that, The pharmaceutical composition further comprises a pharmaceutically acceptable carrier or excipient.

9. The pharmaceutical composition of claim 8, wherein, The pharmaceutically acceptable carrier or excipient is selected from at least one of a solvent, a diluent, a disintegrant, a precipitation inhibitor, a surfactant, a glidant, a binder, a lubricant, a dispersant, a suspending agent, an isotonic agent, a thickening agent, an emulsifying agent, a preservative, a stabilizer, a hydrating agent, an emulsification accelerator, a buffer, an absorbent, a coloring agent, a flavoring agent, a sweetening agent, an ion exchanger, a release agent, a coating agent, a flavoring agent or an antioxidant.

10. The pharmaceutical composition according to any one of claims 5-7, characterized in that, The pharmaceutical composition is formulated as any one of a powder, a tablet, a capsule, a pill, a dripping pill, a lotion, a suspension or a tincture.

Images